Humacyte Q3 2025 revenue $753K from Symvess launch; net loss narrows to $17.5M; raises $56.5M post-quarter

Humacyte, Inc.

2025-Q3 EPS reported -$0.11 revenue$1,571,000

Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.
Net loss $17.5M in Q3 vs $39.2M in Q3 2024, improved on non-cash contingent earnout remeasurement.
Cash $19.8M at Sep 30; subsequent $56.5M net proceeds from stock/warrant sale.
Symvess: 25 VAC approvals (92 hospitals eligible); 16 hospitals ordered, majority re-orders.
Pipeline: positive V007 2-year dialysis data; IND submitted for CABG; supplemental BLA planned H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.